NPACT- Naturally occuring Plant based Anticancerous Compound-Activity-Target DataBase

Compound: Genistein

ModelsTargetInhibitory ConcRemarkReference
SCID mice bearing orthotopically implanted pancreatic tumor cells, COLO 357 and L3.6pNF-kappaB-In vivo results were similar to in vitro findings, suggesting that the inactivation of NF-kappaB is at least one of the molecular mechanisms by which genistein potentiates gemcitabine-induced antitumor activity in experimental animal model16204081
human SG7901 cells injected into subcutaneous tissue of nude mice was establishedBcl-2-Genistein 0.5, 1 and 1.5 mg/kg significantly inhibited carcinoma growth when it was injected near the tumor by 10.8%, 29.9% and 39.6%, respectively. The apoptosis index was increased progressively with increasing genistein dose (28.9% ± 1.2%, 33.8% ± 1.6% and 37.7% ± 1.2%) . The positive rate of bax protein was increased progressively (0.9% ± 1.7%, 24.9% ± 0.8% and 29.6% ± 1.7%) by by immunohistochemical staining, with increasing dose of genistein. The density of bax mRNA increased progressively with elongation of time by RT-PCR.18203299
human SG7901 cells injected into subcutaneous tissue of nude mice was establishedBax-Genistein 0.5, 1 and 1.5 mg/kg significantly inhibited carcinoma growth when it was injected near the tumor by 10.8%, 29.9% and 39.6%, respectively. The apoptosis index was increased progressively with increasing genistein dose (28.9% ± 1.2%, 33.8% ± 1.6% and 37.7% ± 1.2%) . The positive rate of Bcl-2 protein was decreased progressively (11.9% ± 0.9%, 5.9% ± 0.7% and 4.2% ± 0.6%) by immunohistochemical staining, with increasing dose of genistein. The density of Bcl-2 mRNA decreased progressively with elongation of time by RT-PCR.18203299
TSGH8301 cells in SCID mice were treated with genistein--The 50 -70-fold increase in tumor size observed over a 2-3-week period in animals treated with DMSO was significantly decreased when genistein10656454

 






Copyright © 2012. Subhash M. Agagrwal. All Rights Reserved.